3rd edition Unmet challenges in high risk hematological malignancies: from benchside to clinical practice

Turin, September 21-22, 2023 Starhotels Majestic *Scientific board:* **Marco Ladetto** (Alessandria) **Umberto Vitolo** (Candiolo-TO)

Disclosures of Georg Hess

-**Consultancy**: Abbvie, ADC-Therapeutics, AstraZenaeca, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Miltenyi, Novartis, Roche

- -Honoraria: Abbvie, AstraZeneca, Beigene, BMS, Genmab, Gilead/Kite, Incyte, Janssen, Lilly, Roche
- -Research Funding: Abbvie, Gilead/Kite, Incyte, Janssen, Morphosys, Roche
- -Patents and Royalties: not applicable
- -Membership on an entity's Board of Directors or advisory committees: not applicable
- -Discussion of off-label drug use: not applicable
- -Travel grants: Gilead/Kite, Janssen


Mantle cell lymphoma – First line treatment – focus on High Risk

Georg Heß | Department of Hematology and Medical Oncology | University Medical School of the Johannes Gutenberg-University, Mainz, Germany





UNIVERSITĀTS**medizin**. uct | Universitāres Centrum für Tumorerkrankungen MAINZ



Development steps of treatment of MCL

-Establishment of

- Dose intensification (HDT)
- Introduction of especially active cytostatics (cytarabinosid, bendamustine)
- Identification of effective targeted agents (Proteasome inhibitors, BTKi, BCL-2i, Celmods)
- Introduction of T-cell engaging therapies

Development steps of treatment of MCL


-Establishment of

- Dose intensification (HDT)
- Introduction of especially active cytostatics (cytarabinosid, bendamustine)
- Identification of effective targeted agents (Proteasome inhibitors, BTKi, BCL-2i, Celmods)
- Introduction of T-cell engaging therapies


-Work in progress

- Combination approaches
- Tailoring of treatment based on individual risk profiles.

MIPI-C is valid in elderly and younger



Ki67 high OR p53 ICH > 50% or Blastoid morphology




Dreyling et a. Blood (2019) 134 (Supplement_1): 3996.

First line treatment

Transplant in | eligible !?!


Intensive treatment




Reduced intensity treatment

Chemoimmunotherapy as SOC

- R-CHOP superior to R-FC
- R maintenance superior to IFN
- RB equivalent to R-CHOP
- Role of Rm after RB not formaly proven, but reasonable evidence
- VR-CAP superior to CHOP
- R-BAC intensive alternative with long term remissions





12 24 36 48 60 72 84

Time (months)


48

Time (months)

Maintenance rituximab (MR) after first-line BR or R-CHOP in patients with MCL from a large US real-world cohort

Real world TTNT





MR was associated with improved rwTTNT and rwOS with both BR and R-CHOP

SHINE - Trial Design




- Previously untreated MCL
- ≥ 65 years of age
- Stage II-IV disease
- No stem cell transplant


Stratification factor

Simplified MIPI score (low vs intermediate vs high)

Enrolled between May 2013 and November 2014 in 29 countries and 183 sites




PFS




- Ibrutinib combined with BR and R maintenance demonstrated **a 25% reduction in the relative risk of disease progression or death** versus BR and R maintenance
- Significant improvement in median PFS: 80.6 month (6.7 years) versus 52.9 months (4.4 years) (Δ=2.3 years)

PFS in high risk patients



Overall Survival Similar in Both Arms




Ibrutinib + BR	261	239	221	208	197	187	171	163	158	152	145	138	128	118	70	25	0
Placebo + BR	262	244	223	212	203	197	188	177	171	165	159	154	147	137	90	31	2

NR, not reached.

Chemofree: Ibrutinib | Rituximab

Characteristic	Patients ($N = 5$	0
Median age, years (range)	65 (40-85)
Sex, No. (%)		
Male	33 (66)	
Female	17 (44)	
ECOG 0-1, No. (%)	50 (100)	
Spleen size, cm, median (range)ª	13 (9-29)	
Lymph node size, mmª		
No enlarged and no FDG uptake, No. (%)	11 (22)	
Longest diameter, median (range)	21 (13-43)
BM involvement	44 (88)	
Ann Arbor stage, No. (%)		
1-11	3 (6)	
III-IV	47 (94)	
WBC count ($ imes$ 10 ⁹ /L), median (range)	12.2 (3.7-12	26
PB involvement by flow cytometry, No. (%)	44 of 49 (90)	
Hemoglobin (< 110 g/L), No. (%)	3 (6)	
Platelet count (< 100 $ imes$ 10 ⁹ /L), No. (%)	4 (8)	
Serum LDH (> ULN), No. (%)	4 (8)	
Serum B2-microglobulin (> ULN), No. (%)	22 of 45 (49)	
MIPI, No. (%)		
Low risk	12 (24)	
Intermediate risk	19 (38)	
High risk	19 (38)	




Ibrutinib Rituximab results

		Gene Expression	Profile L-MCL16	TP53			
Response	All Patients (N = 50)	nnMCL (n = 17)	cMCL (n = 14)	Wild-Type ($n = 35$)	Mutated $(n = 6)$		
Overall response	42 (84, 74 to 94)	15 (88)	12 (86)	31 (89)	5 (83)		
CR	40 (80, 69 to 91)	14 (82)	11 (79)	29 (83)	5 (83)		
PR	2 (4, 0 to 9)	1 (6)	1 (7)	2 (6)	—		
SD	3 (6, 0 to 10)	1 (6)	1 (7)	3 (8)	_		
PD	1 (2, 0 to 6)	1 (6)	—	—	1 (17)		
Nonevaluableª	4 (8, 0 to 15)	_	1 (7)	1 (3)	_		


NOTE. Data are No. (%, 95% CI).

Abbreviations: cMCL, conventional MCL molecular subtype; CR, complete response; IR, ibrutinib, rituximab combination; MCL, mantle cell lymphoma; nnMCL, non-nodal MCL molecular subtype; PD, progressive disease; PR, partial response; SD, stable disease.


^aFour patients were nonevaluable at 12 months of treatment because of treatment discontinuation: severe a plastic anemia, skin rash, and withdrawal consent because of treatment intolerance and unrelated event with vertebral fractures.



MDA-experience




Key Trials: ENRICH



https://doi.org/10.1186/ISRCTN11038174

EMCL-elderly 2023: VIRAL – Phase II




Transplant in eligible !?!

Intensive treatment




Reduced intensity treatment

Randomized trial of the EMCL-network



High-Dose Cytarabine clinical **Stem-Cell Transplanta** Lymphoma: Long-Term **Randomized Mantle C Trial of the European** Lymphoma Network


Olivier Hermine, MD, PhD^{1,2}; Linmiao Jiang, MSc³; Jan Walews **R-CHOP** Michal Szymczyk, MD⁴; Christiane Pott, MD, PhD⁷; Gilles Salles **R-DHAP** Corinne Haioun, MD, PhD¹²; René Olivier Casasnovas, MD¹³; Chr Lothar Kanz, MD, PhD¹⁷: Jan Dürig, MD, PhD¹⁸: Bernd Metzner



No. at risk:

232 194 175 160 135 115 100 77 65 61 53


Time (years)



No. at risk:

R-CHOF R-DHA 196 174 155 141 121 103 94 85 70 51

No heterogeneity of treatment effects was seen in subgroup analyses for sex, MIPI, Ki-67, MIPI-c, and cytology (Data Supplement). Efficacy of cytarabine tended to be stronger with high p53 expression (> 50%) and for highrisk MCL.




trial updates

TP53 mutation in HDT-treated patients

LYMPHOID NEOPLASIA

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy


Christian W. Eskelund,^{1,2} Christina Dahl,³ Jakob W. Hansen,^{1,2} Maj Westman,⁴ Arne Kolstad,⁵ Lone B. Pedersen,¹ Carmen P. Montano-Almendras,^{1,2} Simon Husby,^{1,2} Catja Freiburghaus,⁶ Sara Ek,⁶ Anja Pedersen,^{1,2} Carsten Niemann,¹ Riikka Räty,⁷ Peter Brown,¹ Christian H. Geisler,¹ Mette K. Andersen,⁴ Per Guldberg,³ Mats Jerkeman,⁸ and Kirsten Grønbæk^{1,2}



Eskelund et al., Blood 2017; DOI 10.1182/blood-2017-04-779736; Rule et al. | Haematologica | 2019; 104(5):e211-e214

Including unapproved information in Japan


Alternative induction treatment




858

10 MARCH 2020 · VOLUME 4, NUMBER 5

Alternative induction treatment



De-escalation for induction treatment







Figure 3. Time to next treatment comparisons between R-B and R-CHOP/ R-DHAP.

TRIANGLE: study design

- MCL patients
- previously untreated
- stage II-IV
- younger than 66 years
- suitable for HA and ASCT
- ECOG 0-2
- Primary outcome:
 - FFS


- Secondary outcomes:


- Response rates
- PFS, RD
- OS
- Safety



- R maintenance was added following national guidelines in all 3 trial arms
- Rituximab maintenance (without or with Ibrutinib) was started in 168 (58 %)/165 (57 %)/158 (54 %) of A/A+I/I randomized patients.

Triangle: A+I vs I






Num	bers At	Risk					n	nonth	ns fro	m rai	ndon	nisati	on
Α	288	252	237	206	162	126	85	54	27	12	2	0	
A+I	292	270	253	226	184	137	109	65	40	17	3	1	
1	290	269	257	229	180	133	100	68	34	16	4	3	

 Test A+I vs. I ongoing, no decision yet

Next lymphoma treatment (among patients with first treatment failure)	(n:	A =68)		4+I =35)	I (n=37)		
Treatment with Ibrutinib	34	79%	4	24%	3	11%	
Treatment without Ibrutinib	9	21%	13	76%	24	89%	
No treatment	25		18		10		

A arm: R-CHOP/R-DHAP+ASCT; A+I arm: IR-CHOP/R-DHAP+ASCT+I; I arm: IR-CHOP/R-DHAP+I. I: ibrutinib


Triangle: overall survival



TRIANGLE: FFS Superiority of A+I vs. A




p53: Low (<=50%)




A arm: R-CHOP/R-DHAP+ASCT; A+I arm: IR-CHOP/R-DHAP+ASCT+I

Today age still dominates treatment recommendation




EMCL-Trial strategy for HighRisk CAR-T in firstline



Summary

- -Mantle Cell Lymphoma prognosis has improved over the recent years
 - Introducion of ARA-C, Rm and in the past HDT
 - Introduction of BTK in relapse and now firstline, at least for younger patients
- -High risk definition
 - Still can not be used for treatment recommendation in every patient
 - In younger: TRIANGLE like treatment would be the primary choice
 - In elderly patients optimal treatment yet to be defined
 - Waiting especially for results of ENRICH, OASIS, VIRAL
 - Incorporation of new approaches (CAR's, Bispecs etc) highly attractive.

Understand treatment pathways





> 1500 patients included
10 countries open
Open for cooperation / collaboration
→ www.emcl-register.net

Thank you | Discussion

